Ryan Fischer

A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy

Holly L. Peay, Ilene L. Hollin, Ryan Fischer et al. · Clinical Therapeutics · 2014 · 111 citations · Full text

Pharmacy, Health Policy, Community Engagement +16

How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration

Pat Furlong, John F. P. Bridges, Lawrence Charnas et al. · Orphanet Journal of Rare Diseases · 2015 · 44 citations · Full text

Pharmacy, Health Policy, Clinical Trial Regulation +15

Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents

Holly L. Peay, Ryan Fischer, Janice Tzeng et al. · PLoS ONE · 2019 · 44 citations · Full text

Medicine, Molecular Medicine, Gene Therapy +12

Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study

Norah L. Crossnohere, Ryan Fischer, Andrew Lloyd et al. · Medical Decision Making · 2021 · 37 citations

Pharmacy, Pharmacoeconomics, Health Assessment +16

Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients

Ryan S. Paquin, Ryan Fischer, Carol Mansfield et al. · Orphanet Journal of Rare Diseases · 2019 · 36 citations · Full text

Pharmacy, Biostatistics, Translational Sciences +15